Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
13.49
-0.18 (-1.32%)
Nov 3, 2025, 4:00 PM EST - Market closed
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,526,941
Market Cap
27.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CVKD News
- 5 weeks ago - Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewsWire
- 7 weeks ago - Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors - GlobeNewsWire
- 3 months ago - Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 3 months ago - Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis - Business Wire
- 5 months ago - Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - Business Wire
- 5 months ago - Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - Business Wire
- 6 months ago - Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
- 6 months ago - Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - Business Wire